Risk of Metabolic Complications in Patients with Solid Tumors Treated with mTOR inhibitors: Meta-analysis

open access:
Risk of Metabolic Complications in Patients with Solid Tumors Treated with mTOR inhibitors: Meta-analysis

 Despite its limitations, this study demonstrates that the use of mTORi is associated with a significant risk of developing all- and high-grade metabolic complications. The risk of adverse metabolic events does not differ by type of Rapamycin analog, type of malignancy treated, or when monotherapy or concomitant therapy is utilized. Early detection and effective management of HGL, HTG, and HCE may allow for more extensive use of mTORi therapy, especially in cancer patients with pre-existing metabolic comorbidities, and should limit treatment related toxicity.